Identification of LRG1 targeting peptide and its application in targeted imaging for breast cancer  

作　　者：Mengdie Chen Anying Zhu Furong Zhu Ziwen Lei Tao Huang Shengnan Du Dongdong Wang Xiaoyu Zhang Huan Min Yingqiu Qi Guangjun Nie 

机构地区：[1]Department of Pharmacology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China [2]Institute of Advanced Technology,Zhengzhou University,Zhengzhou 450008,China [3]Department of General Surgery,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China [4]Department of Breast Disease,The Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital,Zhengzhou 450003,China [5]CAS Key Laboratory of Separation Science for Analytical Chemistry,Dalian Institute of Chemical Physics,Chinese Academy of Sciences,Dalian 116023,China [6]CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety&CAS Center for Excellence in Nanoscience,National Center for Nanoscience and Technology of China,Beijing 100190,China

出　　处：《Nano Research》2024年第10期9044-9051,共8页纳米研究（英文版）

基　　金：supported by grants from the National Natural Science Foundation of China(Nos.32000998 and 32201240);The Young Elite Scientists Sponsorship Program by Henan Association for Science and Technology(No.2022HYTP046);the China Postdoctoral Science Foundation(No.2021TQ0298);Science and Technology Development Project of Henan Province(Nos.222102310525,232102310351);National College Students’innovation and entrepreneurship training program(No.202310459197).

摘　　要：Breast cancer remains a leading cause of morbidity and mortality among women worldwide,emphasizing the urgent need for enhanced diagnostic and therapeutic approaches.Leucine-rich-alpha-2-glycoprotein 1(LRG1)has emerged as a notable target due to its markedly elevated expression in breast tumors,suggesting the viability of LRG1 as a theranostic target.In our study,we employed phage display technology to identify a peptide,termed ET,that binds to LRG1 with a dissociation constant of 48.4μM.After modified with fluorescent cyanine dye,the ET peptide showcased effective tumor-targeting imaging across three different primary breast tumor models and a metastatic breast tumor model.We also undertook a comprehensive safety evaluation,which verified the good biosafety credentials of ET peptide.In summary,the ET peptide identified in this study shows effective LRG1-targeting ability both in vitro and in vivo,thus exhibiting immense potential for clinical translation.

关 键 词：breast cancer leucine-rich-alpha-2-glycoprotein 1(LRG1) phage display PEPTIDE tumor targeting 

分 类 号：R730.5[医药卫生—肿瘤]